DT-Web

DB01269 - Panitumumab


Identification
Name Panitumumab
Accession Number DB01269
Type biotech
Description Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight Not Available
Groups approved
Monoisotopic Weight Not Available
Pharmacology
Indication For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
Mechanism of action Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.
Absorption Not Available
Protein binding Not Available
Biotransformation Not Available
Route of elimination Not Available
Toxicity Panitumumab was shown to cause skin, ocular and mucosal related toxicities in 90% of patients receiving panitumumab. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage, were reported.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available

Targets


Epidermal growth factor receptor
Name Epidermal growth factor receptor
Gene Name EGFR
Pharmacological action yes
Actions suppressor
References
  • Lynch DH, Yang XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002 Feb;29(1 Suppl 4):47-50. - Pubmed
  • Cohen RB: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003 Feb;2(4):246-51. - Pubmed
  • Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. - Pubmed
  • Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005 Sep;16(9):1425-33. Epub 2005 Jul 12. - Pubmed
  • Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R: Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s. - Pubmed
  • Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. - Pubmed
  • Keating GM: Spotlight on panitumumab in metastatic colorectal cancerdagger. BioDrugs. 2010 Aug 1;24(4):275-8. - Pubmed
  • Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. - Pubmed
  • Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. - Pubmed
  • Jean GW, Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008 Jun;28(6):742-54. - Pubmed
  • Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 0.5234

Predictions


Id Partner name Gene Name Score
567 Receptor tyrosine-protein kinase erbB-2 ERBB2 0.0729
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0482
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0436
1588 Multidrug resistance protein 1 ABCB1 0.0341
5300 Antigen peptide transporter 1 TAP1 0.0229
4512 Cytochrome P450 3A4 CYP3A4 0.0225
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0224
2782 Complement C1s subcomponent C1S 0.0221
4118 Cytochrome P450 3A5 CYP3A5 0.0218
3817 Complement C1q subcomponent subunit C C1QC 0.0202
3816 Complement C1q subcomponent subunit B C1QB 0.0202
3815 Complement C1q subcomponent subunit A C1QA 0.0202
1102 Low affinity immunoglobulin gamma Fc region receptor III-B FCGR3B 0.02
3818 Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A 0.02
3819 Low affinity immunoglobulin gamma Fc region receptor II-a FCGR2A 0.02
3821 Low affinity immunoglobulin gamma Fc region receptor II-c FCGR2C 0.02
3814 Complement C1r subcomponent C1R 0.02
3820 Low affinity immunoglobulin gamma Fc region receptor II-b FCGR2B 0.0198
784 High affinity immunoglobulin gamma Fc receptor I FCGR1A 0.0191
587 Serum albumin ALB 0.0176
3950 Cell division protein kinase 9 CDK9 0.0171
3968 Cell division protein kinase 8 CDK8 0.0171
4924 Cytochrome P450 2C8 CYP2C8 0.016
5787 Angiopoietin-1 receptor TEK 0.0158
3959 Cell division protein kinase 4 CDK4 0.015
3482 Cell division protein kinase 7 CDK7 0.0148
3955 Cell division protein kinase 6 CDK6 0.0138
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.013
183 Vascular endothelial growth factor A VEGFA 0.013
6016 Cytochrome P450 2C19 CYP2C19 0.0129
4119 Cytochrome P450 2D6 CYP2D6 0.0125
1742 D-HSCDK2 CDK2deltaT 0.0119
1771 Cell division control protein 2 homolog CDK1 0.0119
3321 Cell division control protein 2 homolog CRK2 0.0119
1058 Cell division protein kinase 5 CDK5 0.0116
6024 Cytochrome P450 1A1 CYP1A1 0.0115
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0113
4757 Cytochrome P450 2C9 CYP2C9 0.0087
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0085
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0082
862 Multidrug resistance-associated protein 1 ABCC1 0.0079
4200 Cytochrome P450 1A2 CYP1A2 0.0078
1152 Glycogen phosphorylase, muscle form PYGM 0.0077
2240 Cell division protein kinase 2 CDK2 0.0064
198 Sodium channel protein type 10 subunit alpha SCN10A 0.0063
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0062
1898 Cytochrome P450 1B1 CYP1B1 0.0062
3811 Cytochrome P450 19A1 CYP19A1 0.006
6106 Cytochrome P450 2C18 CYP2C18 0.0056
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0055
118 Organic cation/carnitine transporter 2 SLC22A5 0.0049
5718 Cytochrome P450 2A6 CYP2A6 0.0046
6030 Cytochrome P450 2B6 CYP2B6 0.0042
6107 Cytochrome P450 3A7 CYP3A7 0.0041
↑